Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis

Alessandro Loglio, Peter Ferenci, Sara Colonia Uceda Renteria, Christine Y.L. Tham, Caroline Scholtes, Heidemarie Holzmann, Florian van Bömmel, Marta Borghi, Riccardo Perbellini, Alessandro Rimondi, Elisa Farina, Elena Trombetta, Maria Manunta, Laura Porretti, Daniele Prati, Ferruccio Ceriotti, Fabien Zoulim, Antonio Bertoletti, Pietro Lampertico

Research output: Contribution to journalArticlepeer-review


The entry inhibitor bulevirtide (BLV) received conditional approval from the EMA in July 2020 for the treatment of adult patients with compensated chronic hepatitis delta. However, the effectiveness and safety of BLV administered as monotherapy beyond 48 weeks in difficult-to-treat patients with HDV-related cirrhosis is presently unknown. Herein, we describe the first patients with HDV-related compensated cirrhosis who were treated with BLV (10 mg/day as a starting dose) for up to 3 years on a compassionate use program. Patients were also monitored for HBcrAg and HBV RNA levels, and HDV- and HBV-specific T-cell markers. In the patient who stopped BLV at week 48, after achieving a virological and biochemical response, the initial virological and biochemical rebound was followed by alanine aminotransferase normalization coupled with low HDV RNA and HBsAg levels. In the 2 patients treated continuously for 3 years, virological and biochemical responses were maintained throughout the treatment period even after dose reduction. In a patient with advanced compensated cirrhosis, liver function tests significantly improved, esophageal varices disappeared, and histological/laboratory features of autoimmune hepatitis resolved. Overall, no safety issues were recorded, as bile salt increase was asymptomatic. While serum HBV RNA levels remained undetectable in all patients, HBV core-related antigen levels showed a progressive, yet modest decline during long-term BLV treatment. No HDV-specific interferon-γ-producing T cells were detected, neither after HDV reactivation (after BLV withdrawn in Patient 1) nor during 3 years of BLV treatment. In conclusion, this report shows that continuous administration of BLV monotherapy for 3 years leads to excellent virological and clinical responses in patients with HDV-related cirrhosis who had contraindications to interferon-based therapies.

Original languageEnglish
Pages (from-to)464-469
JournalJournal of Hepatology
Issue number2
Publication statusPublished - 2022


  • Bulevirtide
  • Entry inhibitor
  • HBcrAg
  • HBV
  • HDV
  • T-cell

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis'. Together they form a unique fingerprint.

Cite this